Clinical Trial Update: Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sargramostim to prevent mucositis in patients receiving radiation therapy for laryngeal cancer. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Laryngeal Cancer

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Head and Neck Cancer, Oral Complications | Phase 2 | Status: COMPLETED